IRB #

STUDY00017583

Title

A Phase 2 open-label study of the CSF1R inhibitor JNJ-40346527 in patients with relapsed/refractory acute myeloid leukemia (AML)

Principal Investigator

Elie Traer

Study Purpose

This study is being performed to determine the efficacy of the CSF1R inhibitor, JNJ-40346527, in participants with relapsed/refractory acute myeloid leukemia (AML). The safety and survival associated with JNJ-40346527 to treat participants with relapsed/refractory AML will be assessed.

Medical Condition(s)

relapsed/refractory acute myeloid leukemia (AML)

Eligibility Criteria

Patients diagnosed with relapsed/refractory acute myeloid leukemia (AML).

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

At least one month or a minimum of 12 months follow-up from the first dose of study drug JNJ-40346527. If there is clinical benefit with treatment study drug will be provided.

Minors Included

No

Contact

Tara Macey
maceyt@ohsu.edu
503-494-3835

Sponsor

Janssen and the Leukemia and Lymphoma Society (LLS)

Recruitment End

09/01/2022

Compensation Provided

No


Go Back